We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio
Unlock the market timeline & signal feed
1,359 signals in the last 90 days.
The order this company entered each market — oldest to newest
Medical Advisor - V&I - HN
92 active postings
Sign up to see the full signal feed
How AstraZeneca's international expansion compares to its competitors
AstraZenecaYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 AstraZenecaYou | 62 | 0 | +221% | 1.3k | 51 |
Diagnostics Science Liason Oncology
View postingBuenos Aires, Buenos Aires Province, Argentina · today
【Medical】ﾒﾃﾞｨｶﾙ本部 ｴﾋﾞﾃﾞﾝｽ&ｵﾌﾞｻﾞﾍﾞｰｼｮﾅﾙﾘｻｰﾁ統括部, Statistician
View postingTokyo, Tokyo, Japan · today
MSL Pleno Oncologia GU - Curitiba ou Porto Alegre
View postingCotia, São Paulo, Brazil · today
Consulta Pública
Active
Consulta Pública
Active
Tomorrow’s healthcare: united by purpose, powered by real-world data and AI
ActiveAstraZeneca presents over 85 abstracts at ASCO 2026, including EMERALD-3 trial results for early-stage liver cancer and CARES study on anselamimab for AL amyloidosis, alongside breast cancer data.
Ascentage Pharma presented updated efficacy and safety data for Olverembatinib (HQP1351) as second-line CML-CP treatment at ASCO 2026, showing 91.3% CCyR and 60.9% MMR at 24 cycles with manageable safety profile.
Ascentage Pharma presented Phase Ib data at ASCO 2026 showing olverembatinib combined with blinatumomab achieved 91% complete response rate in Ph+ BCP-ALL or CML-LBP patients with favorable safety profile.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about AstraZeneca's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
